Please login to the form below
SCCHN
This page shows the latest SCCHN news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
The study assessed the candidate monalizumab in combination with cetuximab compared to cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who
Latest news
-
Bad news for Innate Pharma as BMS-backed drug stumbles
Lirilumab combination fails to show additional benefit in SCCHN patients. French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another ... additional benefit compared to Opdivo alone in
-
NICE expands Merck KGaA’s Erbitux reach
in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN). ... The latest decision extends the recommendation for the previously approved cetuximab in combination with radiotherapy for patients with locally advanced SCCHN.
-
NICE turns down Opdivo for head and neck cancer
platinum chemotherapy - for squamous cell carcinoma of the head and neck (SCCHN), at least in the short term.
-
Opdivo drives growth at BMS, but US sales slow down
BMS has just picked up FDA approval for Opdivo for second-line squamous cell carcinoma of the head and neck (SCCHN), and a European approval in relapsed or refractory classical Hodgkin
-
BMS teams up with Infinity Pharmaceuticals for Opdivo study
of the head and neck (SCCHN), which account for 17% of all new cancer cases in the US each year.
More from news
Approximately 6 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Helen Parfitt joins Research Partnership
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
PCa), Renal Cell Carcinoma (RCC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
-
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch
expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017.
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
